Form 4: Guardant Health Officer Reports Stock Transactions

Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported transactions involving restricted stock units and common stock.

Summary

• Chris Freeman, Chief Commercial Officer at Guardant Health, Inc., reported several transactions on April 1, 2026.
• These transactions involved the acquisition of common stock through the vesting of restricted stock units (RSUs) and the disposal of shares to cover tax withholding obligations.
• Freeman acquired a total of 10,211 shares of common stock through the vesting of RSUs.
• Additionally, 4,750 shares were disposed of to cover tax withholding obligations related to the vesting of RSUs, with a transaction price of $91.15 per share.
• Following these transactions, Freeman beneficially owns 60,034 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports standard insider transactions related to equity compensation and tax obligations, without indicating significant buying or selling pressure.

Positives

• Vesting of restricted stock units indicates continued equity-based compensation and potential alignment of management interests with shareholders.
• Acquisition of 10,211 shares of common stock through RSU vesting.

Negatives

• Disposal of 4,750 shares to cover tax withholding obligations, which reduces the net shares held by the reporting person.

Risks

• The disposal of shares for tax withholding could be interpreted as a need for liquidity by the executive, though it is a standard practice upon vesting.
• The transaction price of $91.15 for the disposed shares might be relevant if it's significantly different from the current market price, though no current market price is provided in the filing.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports past transactions.

Management Comments

• The filing includes a signature by an attorney-in-fact, indicating that Chris Freeman authorized another party to sign on his behalf.
• Explanations detail the nature of the restricted stock unit awards, their vesting schedules, and the reason for share retention for tax withholding.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The activity reported by Guardant Health's Chief Commercial Officer is typical for executives receiving equity compensation, involving vesting of RSUs and subsequent share retention for tax purposes.

Stakeholder Impact

• Shareholders: The disposal of shares for tax withholding is a standard practice and does not inherently signal a negative outlook, but it does reduce the executive's net holdings.
• Employees: The vesting of RSUs reinforces the company's use of equity-based compensation to attract and retain talent.
• Management: The transactions reflect the compensation structure and tax planning for key executives.

Next Steps

• Continued monitoring of future Form 4 filings by Chris Freeman and other Guardant Health insiders for any significant changes in beneficial ownership.
• Analysis of Guardant Health's overall financial performance and strategic updates in conjunction with insider trading activity.

Key Dates

Keywords

Guardant Health, GH, Form 4, SEC Filing, Insider Trading, Stock Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Chris Freeman, Chief Commercial Officer